Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy.
Boogaerts MA, Maertens J, Van Der Geest R, Bosly A, Michaux JM, Van Hoof A, Cleeren M, Wostenborghs R, De Beule K. Boogaerts MA, et al. Among authors: van der geest r, van hoof a. Antimicrob Agents Chemother. 2001 Mar;45(3):981-5. doi: 10.1128/AAC.45.3.981-985.2001. Antimicrob Agents Chemother. 2001. PMID: 11181397 Free PMC article. Clinical Trial.
Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
Vandenberghe P, Wlodarska I, Michaux L, Zachée P, Boogaerts M, Vanstraelen D, Herregods MC, Van Hoof A, Selleslag D, Roufosse F, Maerevoet M, Verhoef G, Cools J, Gilliland DG, Hagemeijer A, Marynen P. Vandenberghe P, et al. Among authors: van hoof a. Leukemia. 2004 Apr;18(4):734-42. doi: 10.1038/sj.leu.2403313. Leukemia. 2004. PMID: 14973504
Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Hagenbeek A, Carde P, Meerwaldt JH, Somers R, Thomas J, De Bock R, Raemaekers JM, van Hoof A, De Wolf-Peeters C, van Glabbeke M. Hagenbeek A, et al. Among authors: van hoof a, van glabbeke m. J Clin Oncol. 1998 Jan;16(1):41-7. doi: 10.1200/JCO.1998.16.1.41. J Clin Oncol. 1998. PMID: 9440721 Clinical Trial.
Further characterization of morphologically defined typical and atypical CLL: a clinical, immunophenotypic, cytogenetic and prognostic study on 390 cases.
Criel A, Verhoef G, Vlietinck R, Mecucci C, Billiet J, Michaux L, Meeus P, Louwagie A, Van Orshoven A, Van Hoof A, Boogaerts M, Van den Berghe H, De Wolf-Peeters C. Criel A, et al. Among authors: van orshoven a, van hoof a, van den berghe h. Br J Haematol. 1997 May;97(2):383-91. doi: 10.1046/j.1365-2141.1997.402686.x. Br J Haematol. 1997. PMID: 9163605 Free article.
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
Houot R, Cartron G, Bijou F, de Guibert S, Salles GA, Fruchart C, Bouabdallah K, Maerevoet M, Feugier P, Le Gouill S, Tilly H, Casasnovas RO, Moluçon-Chabrot C, Van Den Neste E, Zachee P, Andre M, Bonnet C, Haioun C, Van Hoof A, Van Eygen K, Molina L, Nicolas-Virelizier E, Ruminy P, Morschhauser F. Houot R, et al. Among authors: van hoof a, van eygen k, van den neste e. Leukemia. 2019 Mar;33(3):776-780. doi: 10.1038/s41375-018-0282-y. Epub 2018 Oct 5. Leukemia. 2019. PMID: 30291335 Free article. Clinical Trial. No abstract available.
180 results